Effects of Botulinum Toxin Type A on the Psychosocial Features of Myofascial Pain TMD Subjects: A Randomized Controlled Trial.

IF 1.9 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Journal of Oral & Facial Pain and Headache Pub Date : 2021-09-01 DOI:10.11607/ofph.2917

Giancarlo De la Torre Canales, Rodrigo Lorenzi Poluha, Yeidi Natalia Alvarez Pinzón, Paulo César Rodrigues Conti, Daniele Manfredini, Alfonso Sánchez-Ayala, Célia Marisa Rizzatti-Barbosa

{"title":"Effects of Botulinum Toxin Type A on the Psychosocial Features of Myofascial Pain TMD Subjects: A Randomized Controlled Trial.","authors":"Giancarlo De la Torre Canales, Rodrigo Lorenzi Poluha, Yeidi Natalia Alvarez Pinzón, Paulo César Rodrigues Conti, Daniele Manfredini, Alfonso Sánchez-Ayala, Célia Marisa Rizzatti-Barbosa","doi":"10.11607/ofph.2917","DOIUrl":null,"url":null,"abstract":"Aims: To determine the effects of botulinum toxin type A (BoNT-A) on the psychosocial features of patients with masticatory myofascial pain (MFP).Methods: A total of 100 female subjects diagnosed with MFP were randomly assigned into five groups (n = 20 each): oral appliance (OA); saline solution (SS); and three groups with different doses of BoNT-A. Chronic pain-related disability and depressive and somatic symptoms were evaluated with the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) Axis II instruments at baseline and after 6 months of treatment. Differences in treatment effects within and between groups were compared using chi-square test, and Characteristic Pain Intensity (CPI) was compared using two-way ANOVA. A 5% probability level was considered significant in all tests.Results: Most patients presented low pain-related disability (58%), and 6% presented severely limiting, high pain-related disability. Severe depressive and somatic symptoms were found in 61% and 65% of patients, respectively. In the within-group comparison, BoNT-A and OA significantly improved (P < .001) scores of pain-related disability and depressive and somatic symptoms after 6 months. Only the scores for pain-related disability changed significantly over time in the SS group. In the between-group comparison, BoNT-A and OA significantly improved (P < .05) scores of all variables at the final follow-up when compared to the SS group. No significant difference was found between the BoNT-A and OA groups (P > .05) for all assessed variables over time.Conclusion: BoNT-A was at least as effective as OA in improving pain-related disability and depressive and somatic symptoms in patients with masticatory MFP.","PeriodicalId":48800,"journal":{"name":"Journal of Oral & Facial Pain and Headache","volume":"35 4","pages":"288-296"},"PeriodicalIF":1.9000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral & Facial Pain and Headache","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.11607/ofph.2917","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 5

Abstract

Aims: To determine the effects of botulinum toxin type A (BoNT-A) on the psychosocial features of patients with masticatory myofascial pain (MFP).

Methods: A total of 100 female subjects diagnosed with MFP were randomly assigned into five groups (n = 20 each): oral appliance (OA); saline solution (SS); and three groups with different doses of BoNT-A. Chronic pain-related disability and depressive and somatic symptoms were evaluated with the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) Axis II instruments at baseline and after 6 months of treatment. Differences in treatment effects within and between groups were compared using chi-square test, and Characteristic Pain Intensity (CPI) was compared using two-way ANOVA. A 5% probability level was considered significant in all tests.

Results: Most patients presented low pain-related disability (58%), and 6% presented severely limiting, high pain-related disability. Severe depressive and somatic symptoms were found in 61% and 65% of patients, respectively. In the within-group comparison, BoNT-A and OA significantly improved (P < .001) scores of pain-related disability and depressive and somatic symptoms after 6 months. Only the scores for pain-related disability changed significantly over time in the SS group. In the between-group comparison, BoNT-A and OA significantly improved (P < .05) scores of all variables at the final follow-up when compared to the SS group. No significant difference was found between the BoNT-A and OA groups (P > .05) for all assessed variables over time.

Conclusion: BoNT-A was at least as effective as OA in improving pain-related disability and depressive and somatic symptoms in patients with masticatory MFP.

查看原文本刊更多论文

A型肉毒毒素对肌筋膜疼痛TMD患者心理社会特征的影响:一项随机对照试验。

目的:探讨A型肉毒毒素(BoNT-A)对咀嚼肌筋膜痛(MFP)患者心理社会特征的影响。方法:将100例确诊为MFP的女性受试者随机分为5组(每组20例):口腔矫治器(OA);生理盐水(SS);三组注射不同剂量的BoNT-A。在基线和治疗6个月后，使用颞下颌疾病研究诊断标准(RDC/TMD) II轴仪器对慢性疼痛相关残疾、抑郁和躯体症状进行评估。采用卡方检验比较组内和组间治疗效果的差异，采用双因素方差分析比较特发性疼痛强度(CPI)。在所有测试中，5%的概率水平被认为是显著的。结果:大多数患者表现为低疼痛相关残疾(58%)，6%表现为严重限制，高疼痛相关残疾。严重的抑郁和躯体症状分别在61%和65%的患者中发现。在组内比较中，BoNT-A和OA在6个月后显著改善了疼痛相关残疾、抑郁和躯体症状评分(P < 0.001)。在SS组中，只有疼痛相关残疾的得分随时间发生了显著变化。在组间比较中，与SS组相比，BoNT-A和OA组在最终随访时各变量得分均显著提高(P < 0.05)。在BoNT-A组和OA组之间，所有评估变量随时间的变化均无显著差异(P > 0.05)。结论:BoNT-A在改善咀嚼性MFP患者的疼痛相关残疾、抑郁和躯体症状方面至少与OA一样有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oral & Facial Pain and Headache DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

5.10

自引率

4.00%

发文量

期刊介绍： Founded upon sound scientific principles, this journal continues to make important contributions that strongly influence the work of dental and medical professionals involved in treating oral and facial pain, including temporomandibular disorders, and headache. In addition to providing timely scientific research and clinical articles, the journal presents diagnostic techniques and treatment therapies for oral and facial pain, headache, mandibular dysfunction, and occlusion and covers pharmacology, physical therapy, surgery, and other pain-management methods.